Phase 1/2Data readout

Efarindodekin Alfa (XTX301)

Solid tumor/s

XLOXilio Therapeutics

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: Efarindodekin Alfa (XTX301)
Development stage: Phase 1/2
Event type: Data readout
Indication: Solid tumor/s

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for Efarindodekin Alfa (XTX301) in Solid tumor/s. The expected timing is based on the latest available company guidance and may change.

Development notes

3/28/24- Partnered w/GILD. 12/19/24- Reported preliminary data. 5/8/25- Maximum tolerated dose not yet established. 9/9/25- Ph2 trial initiated. 11/13/25:- SITC Ph1 monotherapy data showed promising anti-tumor activity and well-tolerated safety; RP2D selected, Ph2 dosing ongoing, and Ph1A/Ph1B enrollment completed with evaluation continuing. 01/08/26:- Deliver Ph1/2 option data package to Gilead for efarindodekin alfa in H1 2027. 03/23/26:- Expects to deliver Gilead option data package from ongoing Ph2 monotherapy trial in H1 2027. 05/12/26:- Reiterates plan to deliver Gilead option data package for efarindodekin alfa in H1 2027. 08/12/26:- Ongoing Ph2 monotherapy trial continues. Gilead option data package is expected in H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for Efarindodekin Alfa (XTX301) in Solid tumor/s. The expected timing is based on the latest available company guidance and may change.